Leigh Zawel

Leigh Zawel

Company: Cullinan Oncology/MPM Capital

Job title: Chief Scientific Officer/Executive Partner


Discovery and Early Clinical Development of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 Insertion Mutations 11:30 am

Challenges in the discovery of an Ex20 targeted therapy Preclinical characterization of CLN-081 in models of Ex20 NSCLC Safety and early signs of efficacy in patients with Ex20 NSCLCRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.